50% Imaging Error Rate in Clinical Trials Discussed by Expert Panelists from 5 NCI-Designated Cancer Centers
Data points to a broader industry-wide imaging accuracy crisisCHICAGO, IL / ACCESSWIRE / July 23, 2024 / Yunu, a provider...
News
David Rubenstein Joins Moderna’s Board of Directors
Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen BerensonCo-founder...
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics...
The Canadian Foundation for Women’s Health (CFWH) Launches Comprehensive Effort to Combat Maternal Morbidity and Mortality
As Canada's maternal health suffers from ongoing deficiencies, the foundation urges immediate prevention and intervention with a multifaceted approachOTTAWA, July...
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals...
Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware
ROSELAND, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing in the second cohort has commenced following the successful completion of the first cohortGLEN ALLEN, Va., July 23,...
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device
DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first...
Cannara Biotech Reports Q3 2024 Financial Results
Gross cannabis revenues before excise taxes increased to $26.2 million in Q3 2024 from $20.6 million in Q3 2023, a...
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
Paves the Way for Kane’s revyve™ Antimicrobial Wound Gel SprayWINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-...
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday,...
Vireo Growth Inc. to Release Second Quarter 2024 Results on August 6, 2024
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (formerly Goodness Growth Holdings, Inc.) ("Vireo" or the "Company") (CSE:...
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Spectral AI Adds Three New Clinical Trial Sites To Expedite Emergency Department Patient Enrollment
DALLAS, July 23, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome
U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel...
Inspire Medical Systems, Inc. Announces Countrywide Reimbursement in France
MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm...
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Inovalon Launches Provider Market Insights To Empower Life Sciences Organizations With Superior Market Data
SaaS Analytics Solution Provides Life Sciences Insight Into Brand Performance, Provider Engagement, and Patient OutcomesBOWIE, Md., July 23, 2024 (GLOBE...
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc....